Jane bell am appointed chair of mesoblast audit and risk committee

New york, sept. 26, 2023 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that independent director jane bell am has been appointed chair of the mesoblast board audit and risk committee. ms bell joined the board in august 2022, and is a banking and finance lawyer with 30 years of corporate finance expertise focussing on international investment transactions in the united states, canada, australia and the united kingdom, including funds management, mergers, acquisitions, and divestments. the board thanked retiring director and chair of audit and risk committee mr michael spooner for his many years of dedicated service and contributions, and wished him well in his future endeavours.
MESO Ratings Summary
MESO Quant Ranking